Program
solriamfetol
Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.
Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.
Drug pageSolriamfetol: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axsome Therapeuticsits history only | 117 open or running | phase 4since Feb 25, 2021 | Feb 25, 2021 | Dec 2026phase 3 · NCT06413433 |
| Jazz Pharmaceuticalsits history only | 90 open or running | phase 3since Jan 15, 2015 | Dec 2, 2011 | none ahead |
| Ignis Therapeutics (Suzhou)its history only | 10 open or running | phase 3since Sep 27, 2023 | Sep 27, 2023 | none ahead |
| Johnson & Johnson | 10 open or running | phase 2since Nov 17, 2003 | Nov 17, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 17, 2003First study: phase 2 study in Depressive Disorder, MajorFirst studyNCT00073203 · 488 enrolled · United States
- Dec 9, 2016Named solriamfetolINNProposed as its International Nonproprietary Name in WHO's List 116 · before, JZP-110
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Johnson & Johnson leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00073203Depressive Disorder, Major · United States | 2 | Completed | 488 |
How it is read
Names in the registry
- “JZP-110”, 7 entries
- “Solriamfetol”, 4 entries
- “Solriamfetol 300 mg”, 4 entries
- “Solriamfetol 150 mg”, 3 entries
- “Solriamfetol Dose A”, 2 entries
Conditions, from the studies’ own filings
- Narcolepsy, 6 studies
- Attention Deficit Disorder with Hyperactivity, 4 studies
- Sleep Apnea, Obstructive, 4 studies
- Depressive Disorder, Major, 3 studies
- Disorders of Excessive Somnolence, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.